OR WAIT null SECS
March 15, 2025
Article
Our top 5 headlines featured an oral drug delivering 16% weight loss, notable blood pressure reductions from a hypertension treatment, and 3 key FDA decisions.
March 10, 2025
Omalizumab-igec is approved in 2 formulations for the treatment of moderate to severe persistent asthma, CRSwNP, IgE-mediated food allergy, and CSU.
February 21, 2025
Alvotech and Teva announced that the biosimilar will be interchangeable with the reference after ustekinumab-auub’s exclusivity expires in April 2025.
February 18, 2025
Alvotech and Teva expect the review to be completed in the fourth quarter of 2025.
February 04, 2025
Tocilizumab-anoh will be available in both intravenous and subcutaneous formulations.
January 08, 2025
The biosimilars month in review highlights a newly approved ustekinumab biosimilar and a look into the field in 2024.
CT-P42 may help improve access to aflibercept in lower-income countries.
December 26, 2024
December 18, 2024
Celltrion’s CT-P43/ustekinumab-stba has been approved under the name Steqeyma and is expected to launch in February 2025.
December 06, 2024
The biosimilars month in review highlights new equivalency data for denosumab and tocilizumab biosimilars.
